MAB8612
Anti-Varicella-Zoster Virus Antibody, Glycoprotein I
Chemicon®, from mouse
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Productos recomendados
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunofluorescence: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG2b
shipped in
wet ice
Specificity
Recognizes the VZV glycoprotein I by indirect immunofluorescence, immuno-precipitation and Western blotting.
Immunogen
Epitope: Glycoprotein I
VZV HZ strain.
Application
Anti-Varicella-Zoster Virus Antibody, Glycoprotein I is an antibody against Varicella-Zoster Virus for use in IF, IP, WB, IH.
Indirect immunofluorescence: on unfixed cells shows both cytoplasmic and membrane pattern. Staining on fixed cells shows only cytoplasmic pattern.
Immunohistochemistry: reactive on formalin fixed tissue.
Western blot
Immunoprecipitation
Optimal working dilutions must be determined by the end user.
Immunohistochemistry: reactive on formalin fixed tissue.
Western blot
Immunoprecipitation
Optimal working dilutions must be determined by the end user.
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
Physical form
1 mg/mL in 0.02M PB with 0.25M NaCl, pH 7.6, containing 0.1% sodium azide.
Format: Purified
Storage and Stability
Maintain at 2-8°C in undiluted aliquots for up to 12 months.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Storage Class
10 - Combustible liquids
wgk_germany
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Daniel P Depledge et al.
Nature communications, 9(1), 1167-1167 (2018-03-23)
Varicella-zoster virus (VZV), an alphaherpesvirus, establishes lifelong latent infection in the neurons of >90% humans worldwide, reactivating in one-third to cause shingles, debilitating pain and stroke. How VZV maintains latency remains unclear. Here, using ultra-deep virus-enriched RNA sequencing of latently
Varicella-zoster virus ORF12 protein activates the phosphatidylinositol 3-kinase/Akt pathway to regulate cell cycle progression.
Liu, X; Cohen, JI
Journal of virology null
Ryo Takahashi et al.
Journal of immunology (Baltimore, Md. : 1950), 192(3), 969-978 (2014-01-01)
It remains unknown why the occurrence of eczema herpeticum (EH) caused by an extensive disseminated cutaneous infection with HSV-1 or HSV-2 is associated with the exacerbation of atopic dermatitis lesions after withdrawal of treatment. Although regulatory T cells (Tregs) limit
Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts.
Stefan L Oliver, Leigh Zerboni, Marvin Sommer, Jaya Rajamani, Ann M Arvin et al.
Journal of Virological Methods null
Hirobumi Saitoh et al.
Internal medicine (Tokyo, Japan), 52(15), 1727-1730 (2013-08-02)
Disseminated visceral varicella-zoster virus (VZV) infection rarely occurs in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). To date, only a few cases of isolated VZV-induced fulminant hepatitis following allo-HSCT have been reported. We herein describe the case of a
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico